Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-MTHF Supplementation in Type 1 Diabetes
NCT06930144Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
01
Overview
Randomised trial in type 1 diabetes mellitus (T1D) comparing 5-MTHF supplementation group with placebo control group (2 arms). Primary endpoint: Islet beta cell function at 24 weeks. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
5-MTHF
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06930144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06930144.